Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).

Ahn, Chang Ho

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study). [electronic resource] - Diabetes, obesity & metabolism 05 2017 - 635-643 p. digital

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1463-1326

10.1111/dom.12866 doi


Aged
Diabetes Mellitus, Type 2--blood
Dipeptidyl-Peptidase IV Inhibitors--adverse effects
Double-Blind Method
Drug Monitoring
Drug Resistance
Drug Therapy, Combination--adverse effects
Female
Glycated Hemoglobin--analysis
Humans
Hyperglycemia--prevention & control
Hypoglycemia--chemically induced
Hypoglycemic Agents--adverse effects
Incidence
Male
Metformin--adverse effects
Middle Aged
Piperidones--adverse effects
Pyrimidines--adverse effects
Republic of Korea--epidemiology
Risk
Sulfonylurea Compounds--adverse effects